PEER-REVIEWED PUBLICATIONS 1.

Henneman K, Huber VC, and Van Peursem D. Mathematical modeling of influenza and secondary bacterial infection. WSEAS Transaction on Biology and Biomedicine. In Press.

2.

Sun Z, Lawson S, Langenhorst R, McCormick KL, Brunick C, Opriessing T, Baker R, Yoon KJ, Zhang W, Huber VC, and Fang Y. Development of an epitope-based vaccine against swine influenza A virus using Escherichia coli heat-labile toxin B subunit as a carrieradjuvant. Vet. Micro. In Press.

3.

Huber VC. Can surveillance of the influenza virus PB1-F2 gene be used to predict the severity of secondary bacterial infections? Virulence. 3:523-4, 2012.

4.

Sun Z, Huber V, McCormick K, Kaushik RS, Boon ACM, Zhu L, Hause B, Webby RJ, Fang Y. Characterization of a porcine intestinal epithelial cell line for influenza virus production. J Gen Virol. 93:2008-16, 2012.

5.

Weeks-Gorospe JN, Hurtig HR, Iverson AR, Schuneman MJ, Webby RJ, McCullers JA, Huber VC. Naturally occurring swine influenza A virus PB1-F2 phenotypes that contribute to super-infection with Gram-positive respiratory pathogens. J Virol 85:9035-43, 2012.

6.

McCullers JA and Huber VC. Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother 8: 34-44, 2012.

7.

Cwach KT, Sandbulte HR, Klonoski JM, and Huber VC. Contribution of murine innate serum inhibitors toward interference with influenza virus immune assays. Influenza Other Respi Viruses 6:127-35, 2012.

8.

Halasa N, Englund JA, Nachman S, Weinberg GA, Huber VC, Allison K, Dubovsky F, Yi T, McCullers JA, Flynn PM. Safety of Live Attenuated Vaccine in Mild to Moderately Immunocompromised Children With Cancer. Vaccine 29: 4110-5, 2011.

9.

Chaussee MS, Sandbulte HR, Schuneman MJ, DePaula FP, Addengast LA, Schlenker EH, and Huber VC. Inactivated and live, attenuated influenza vaccines protect mice against influenza:Streptococcus pyogenes super-infections. Vaccine 29:3773-81, 2011.

10.

Huber VC, Peltola V, Iverson AR, and McCullers JA. Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications. J Virol 84:4105-4108, 2010.

11.

Huber VC, Thomas PG, and McCullers JA. A multi-valent approach that elicits broad immunity within an influenza subtype. Vaccine 27:1192-1200, 2009.

12.

Huber VC and McCullers JA. Vaccines against pandemic influenza: what can be done before the next pandemic?. Pediatr Infect Dis J 27:S113-S117, 2008.

13.

Huber VC, Kleimeyer LH, and McCullers JA. Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine 26:5381-5388, 2008. 1

14.

Huber VC and McCullers JA. FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther 10:75-85, 2008.

15.

Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DP, MacDonald GH, McCullers JA. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13:981-990, 2006.

16.

Huber VC, McCullers JA. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets. J Infect Dis 193:677-684, 2006.

17.

Huber VC, Mondal T, Factor SA, Seegal RF, Lawrence DA. Serum antibodies from Parkinson's disease patients react with neuronal membrane proteins from a mouse dopaminergic cell line and affect its dopamine expression. J Neuroinflammation 3:1, 2006.

18.

McCullers JA, Hoffman E, Huber VC, Nickerson AD. A single amino acid change in the Cterminal domain of the matrix protein M1 of influenza B virus confers mouse adaptation and virulence. Virology 336:318-326, 2005.

19.

Hudson CA, Mondal TK, Cao L, Kasten-Jolly J, Huber VC, Lawrence DA. The dietary supplement ephedrine induces beta-adrenergic mediated exacerbation of systemic lupus erythematosus in NZM391 mice. Lupus 14:293-307, 2005.

20.

Huber VC, Arulanandam BP, Arnaboldi PM, Elmore MK, Sheehan CE, Kallakury BVS, Metzger DW. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol 3:801-809, 2003.

21.

Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. FcR-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166:7381-7388, 2001.

2